HCI Connects Precision Medicine With Patient-Centered Care

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.

The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.